OptimizeRx Corp

OptimizeRx Corp(OPRX)股票分析

$8.670

-1.015 (-11.71%)收盤時

Loading chart…
最高
9.915
開盤
9.850
成交量加權均價
9.00
成交量
234.62K
市值
188.54M
最低
8.420
成交金額
2.11M
企業價值/稅息折舊攤銷前利潤(TTM)
47.11

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

AI 分析 of OptimizeRx Corp (OPRX)

買進

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

分析師評級(1)

上檔空間 +180.62%
買進
1 買進
0 持有
0 賣出
目前: 8.67
最低
17.00
平均
24.33
最高
32.00

B. Riley

2026-09-29

目標價

$11

買進

Stifel

2026-08-13

目標價

$12

買進

B. Riley

2026-05-13

目標價

$10

買進

Lake Street

2026-05-13

目標價

$11

買進

Stifel

2026-05-13

目標價

$14

買進

估值指標

OptimizeRx Corp(OPRX)目前預期本益比為 6.95,5 年平均預期本益比為 43.69。

預期本益比

低估
5 年均值 P/E
43.69
目前P/E
6.95
高估
77.00
低估
10.38

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
40.57
目前EV/EBITDA
47.11
高估
84.25
低估
-3.12

預期股價營收比

合理
5 年均值 P/S
3.57
目前P/S
1.74
高估
7.13
低估
0.02

Alphio AI 對 OPRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%OPRX

$17.89

情境價格

基

基準

基準 · 50%OPRX

$16.60

情境價格

悲

悲觀

悲觀 · 25%OPRX

$15.41

情境價格

持有 OPRX 的大戶

R

Rice Hall James & Associates, LLC

+ 持有OPRX

+6.45%

3個月報酬率

事件時間軸

2026-10-27 (ET)

08:00:00

OptimizeRx Partners with PulsePoint for Electronic Health Records

2026-09-22 (ET)

09:00:00

OptimizeRx Integrates Supply Path Optimization with The Trade Desk

2026-08-12 (ET)

17:00:00

OptimizeRx Appoints Andy D'Silva as CFO

16:31:00

OptimizeRx Q2 Revenue at $20.5M, Exceeds Expectations

16:30:00

Company Reiterates FY 2026 Guidance, Expects Revenue of $95M to $100M

資訊

OPRX 常見問題 —— 由 Alphio AI 解答

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易